Effects of time-restricted eating on blood pressure in children: A cluster randomized controlled trial.

Clin Exp HypertensFeb 24, 2026 (epub)
Clinical ResearchPediatricsEndocrinology

Xiaofei Wu, Jingkun Miao, Zhilian Peng et al.

✦ AI-curated · Sources linked

In 30 seconds

This 12-month, three-arm cluster-randomized controlled trial in two schools evaluated time-restricted eating (TRE) among 192 children and adolescents with elevated blood pressure. Classes were assigned to a 12-hour eating window with the last meal before 8:00 PM, a 12-hour window without a fixed last mealtime, or no time restriction. Both TRE groups had significant systolic blood pressure reductions: -7.03 mmHg with the fixed mealtime and -5.29 mmHg without it. The fixed-mealtime group also had a significant diastolic reduction and the largest reported changes. Interpretation should account for the cluster design and substantial attrition.

Key findings

  • Systolic blood pressure fell by -7.03 mmHg in TREa (95%CI, -10.77 to -3.29 mmHg; P < 0.001) and -5.29 mmHg in TREb (95%CI, -9.44 to -1.14 mmHg; P = 0.013).
  • In TREa, diastolic blood pressure changed by -4.09 mmHg (-6.80 to -1.38 mmHg; P < 0.001); the change differed significantly from control (P = 0.006).
  • At 12 months, retention was 59.4% (114/192), with loss to follow-up of 40.6% (78/192).

Why it matters

Elevated blood pressure in children and adolescents is a clinically relevant target, and this trial reports lower blood pressure after a structured 12-hour eating window over 12 months. The findings provide evidence for further evaluation of meal timing as a possible behavioral approach, while the observed attrition and cluster-randomized design warrant caution in interpreting the estimates.

What to keep in mind

The trial involved two schools and had substantial attrition: 40.6% of participants were lost to follow-up by 12 months. The authors also advise considering the cluster design.

Source

Published in Clin Exp Hypertens. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.